Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. - Test2 - elhamkhani - TriplyDB

Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

http://www.wikidata.org/entity/Q37263435

about

Role of isavuconazole in the treatment of invasive fungal infections Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections Advances in the treatment of invasive neonatal candidiasis Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Isavuconazole: A New Option for the Management of Invasive Fungal Infections.A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model Antifungal pharmacokinetics and pharmacodynamics Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Isavuconazonium: first global approval.Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.Isavuconazole: a new extended spectrum triazole for invasive mold diseases.Isavuconazole therapy protects immunosuppressed mice from mucormycosis.Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.Recent Advances in the Treatment of Scedosporiosis and Fusariosis.

P2860

Q26740837-63BF4675-24A8-455A-B718-4A8A3E9627D3 Q26744049-42A1E52C-C57E-47ED-885C-0E58AC22FCAF Q27022585-867897F5-355F-431F-AB07-F03E47A33D95 Q27025299-CA323951-2D45-4BDA-A874-9407C0D5E2F7 Q34474946-8625F5A9-478F-4712-99E5-8EAE0FAAC503 Q35076974-64961812-DA4D-476D-8556-7F8233034B70 Q35105763-2133026B-2A9B-49A7-A636-8B74AD230B71 Q35385554-3AD741A4-D5EA-4692-B098-82FD08E320A8 Q35663841-702DA7D0-FDA6-4D6F-B29C-6BDBCA0CBE89 Q37096795-8225ADD0-4591-4D0B-8FC6-CAB3E18D80AE Q37119937-B47A27CB-D5C9-4C02-A18C-AB38F400F50B Q38285488-FCE29A05-E25A-4B8C-AD52-6892FC2DFF56 Q38436002-49F702F4-C980-40DD-888B-D073DA485D7D Q38644817-4606F645-71A8-4918-96D9-30A6FA96461A Q38829932-083D3CB8-9E6B-4DEB-B56E-905B719FBFE4 Q38939506-A3CD4C51-733A-4499-9F95-AF05E9155402 Q38987096-8FBA6D98-CAE7-45F6-82F9-CC458F0FA59D Q39003715-86D8D65E-9A58-4CFB-8E99-CE7207205472 Q39684037-7AC794B7-BC6C-4A09-A557-13725A27D303 Q40045642-B7079A7D-60C1-4B83-B7F4-B10613C017E3 Q40474311-E5768465-5D11-4762-AE42-AD4FED9A627B Q41188300-34BD5F97-8B5F-4E87-962A-7BA6557FE2B4 Q47151374-78ECDE39-97E4-4E7B-BAC2-24D51A47AEEE Q55453637-A730A412-7B87-4169-A0A6-2169883033EF

P2860

Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

http://www.wikidata.org/entity/Q37263435

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Isavuconazole pharmacodynamic ...... isseminated candidiasis model.

@en

Isavuconazole pharmacodynamic ...... isseminated candidiasis model.

@nl

type

label

Isavuconazole pharmacodynamic ...... isseminated candidiasis model.

@en

Isavuconazole pharmacodynamic ...... isseminated candidiasis model.

@nl

prefLabel

Isavuconazole pharmacodynamic ...... isseminated candidiasis model.

@en

Isavuconazole pharmacodynamic ...... isseminated candidiasis model.

@nl

P1433

Q37263435-AAD2364C-DDD3-4BD3-BE37-095D9FC36DD1

P1476

Q37263435-DC2412E6-98D8-4268-A85F-1BA1CBE31671

P2093

Q37263435-2F156262-9621-4ABC-A604-BE17D5D02915

Q37263435-90C44E6B-6E13-497F-AC43-8049F3A5DDBC

Q37263435-C95695D9-7AEF-4FAE-B5B4-EC5E133389CA

P2860

Q37263435-03784C17-BCEB-4776-8672-BB569ABE2234

Q37263435-0BC3E059-AFF2-4044-8C89-E1F92AFD294E

Q37263435-0BFD2357-78AF-453B-9305-C45739CBEF39

Q37263435-0CAC36A1-0D1E-445B-A182-D16FD16B8264

Q37263435-23532793-5FF3-400E-A491-E92729D524E1

Q37263435-247F17A9-AA77-414E-A02F-20AED9C60785

Q37263435-2541C62E-9195-44DC-8775-8D85051DE0E2

Q37263435-2C101965-1D9E-420B-82B3-C3E9F2F7BEC2

Q37263435-2C299A53-3E08-49BF-9792-B80690AA6876

Q37263435-3EF7745A-9D89-46A5-BA20-6D5467FDC061

P304

Q37263435-D47E63CB-0E8F-4F47-8D52-090E851F9A95

P31

Q37263435-06013CBF-7926-4C55-A173-C07361BFFDA2

P356

Q37263435-0CB856D0-7B59-4DA9-ABE7-5C83BE3AE989

P407

Q37263435-58BFE862-B917-41B8-96F0-D8F4148BCE4F

P433

Q37263435-17EA0AE9-AE1B-4C67-BFBE-A9EC3D95F706

P478

Q37263435-99AECFBB-7711-45F5-9CAB-856786F12421

P50

Q37263435-74A9F823-387C-4169-87CE-3ACBF53F02DC

Q37263435-7C42C192-F94F-4EA1-A908-44840403C1B4

P577

Q37263435-6EA2EDEE-17EC-447E-825B-FC6B3FAF923B

P698

Q37263435-C5F588E0-0ACB-4942-8040-2E285692228C

P932

Q37263435-EFA61B5F-7242-485C-91A5-E8B3742F7F6D

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Isavuconazole pharmacodynamic ...... isseminated candidiasis model.

@en

P2093

Alexander J Lepak

http://www.w3.org/2001/XMLSchema#string

Jamie VanHecker

http://www.w3.org/2001/XMLSchema#string

Karen Marchillo

http://www.w3.org/2001/XMLSchema#string

P2860

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

Epidemiology of invasive candidiasis: a persistent public health problem

Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.

Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.

Evaluation of voriconazole pharmacodynamics using time-kill methodology

Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.

In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.

P304

5642-5648

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01354-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Daniel J. Diekema

P577

2013-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24002092

http://www.w3.org/2001/XMLSchema#string

P932

3811283

http://www.w3.org/2001/XMLSchema#string